CYP4Z1-IN-3

CYP4Z1-IN-3 (Compound C8) (0.1-10 μM) potently inhibits CYP4Z1 enzyme activity in lysates from CYP4Z1-overexpressing HEK293T cells with an IC₅₀ of 55.3 nM^[1].
CYP4Z1-IN-3 exhibits high isoform selectivity for CYP4Z1 over human CYP2C9, CYP2C19, CYP2D6, and CYP3A4^[1].
CYP4Z1-IN-3 (60 min) exhibits favorable metabolic stability in CD-1 mouse liver microsomes, with a half-life of 62.4 min and low intrinsic clearance^[1].
CYP4Z1-IN-3 (3 h) shows excellent plasma stability in CD-1 mouse plasma, with a half-life exceeding 3.0 h, while it exhibits poor stability in human plasma^[1].
CYP4Z1-IN-3 (0.01-100 μM; 48 h) does not exhibit significant cytotoxicity in MCF-7 breast cancer cells, MDA-MB-231 breast cancer cells, or normal MCF-10A mammary epithelial cells at concentrations up to 100 μM after 48 h of incubation^[1].
CYP4Z1-IN-3 (0.5-12.5 μM) concentration-dependently reduces expression of stemness markers ALDH1A1, SOX2, and Nanog in CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells, but not in CYP4Z1-negative 4T1 cells^[1].
CYP4Z1-IN-3 (0.5-12.5 μM) concentration-dependently reduces the CD44⁺/CD24⁻ breast cancer stem cell subpopulation in CYP4Z1-expressing MCF-7 and MDA-MB-231 cells, but not in CYP4Z1-negative 4T1 cells^[1].
CYP4Z1-IN-3 (0.5-12.5 μM) dose-dependently suppresses mammosphere formation in CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells, but not in CYP4Z1-negative 4T1 cells^[1].
CYP4Z1-IN-3 (0.5-12.5 μM; 24-48 h) concentration-dependently inhibits the migratory capacity of CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells in wound healing assays^[1].
CYP4Z1-IN-3 (0.5-12.5 μM; 24-48 h) inhibits the invasive capacity of CYP4Z1-expressing MCF-7 and MDA-MB-231 breast cancer cells in Transwell assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.